Most Frequent Early Side Effects
Lurbinectedin (trade name Zepzelca), used for small cell lung cancer, commonly causes side effects within the first few weeks of treatment. The most reported early ones include fatigue (up to 68% of patients), nausea (up to 65%), decreased appetite (up to 50%), and vomiting (up to 37%). These often start soon after infusion and are linked to the drug's impact on rapidly dividing cells.[1][2]
Blood-Related Effects Patients Notice First
Myelosuppression hits early, with neutropenia (low white blood cells, 65%), anemia (58%), and thrombocytopenia (45%) appearing in the first cycle. Patients report tiredness, infections, bruising, or bleeding as symptoms, requiring blood monitoring before each dose.[1][3]
Gastrointestinal Issues in the Initial Cycles
Beyond nausea and vomiting, diarrhea (20-30%) and constipation (15-20%) emerge early. These stem from gut cell turnover disruption and typically peak in weeks 1-2, managed with antiemetics or hydration.[2][4]
Other Early Complaints
Milder effects like headache (20%), dyspnea (shortness of breath, 20%), and musculoskeletal pain (15%) often occur shortly after starting. Liver enzyme elevations (transaminitis, 30%) can appear within days, prompting dose adjustments.[1][3]
How Long Do They Last and What Influences Them?
Early effects usually resolve or lessen by cycle 2 with supportive care, but severity ties to prior chemo exposure or dose (3.2 mg/m² IV every 21 days). Pre-treatment with dexamethasone helps curb nausea.[2][4]
Sources
[1]: Zepzelca Prescribing Information, Jazz Pharmaceuticals (fda.gov) https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/213069s000lbl.pdf
[2]: ClinicalTrials.gov, Study NCT02454972 (IMpower133 companion data) https://clinicaltrials.gov/study/NCT02454972
[3]: ESMO Guidelines on SCLC Management https://www.esmo.org/guidelines/guidelines-by-tumour-type/small-cell-lung-cancer
[4]: NCCN Small Cell Lung Cancer Guidelines v2.2023 https://www.nccn.org/professionals/physiciangls/pdf/sclc.pdf